Conjunctivitis Treatment Market Size, Analysis Report 2024-2032

Conjunctivitis Treatment Market Size - By Drug Class (Antibiotic, Antiviral, Anti-Allergic), Disease Class (Bacterial, Viral, Allergic), Route of Administration (Topical, Oral), Formulation Type, Distribution Channel & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp; Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of conjunctivitis

3.2.1.2&nbsp;&nbsp;&nbsp; Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp; Easy availability and increased awareness levels

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Associated adverse effect of drugs and patent expiration

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Technological landscape

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.6.1&nbsp;&nbsp;&nbsp; Supplier power

3.6.2&nbsp;&nbsp;&nbsp; Buyer power

3.6.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.6.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.6.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

3.8&nbsp;&nbsp;&nbsp; Future market trends

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Antibiotic

5.3&nbsp;&nbsp;&nbsp; Antiviral

5.4&nbsp;&nbsp;&nbsp; Anti-allergic

5.5&nbsp;&nbsp;&nbsp; Artificial tear

5.6&nbsp;&nbsp;&nbsp; Other drug classes

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Class, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Bacterial conjuctivitis

6.3&nbsp;&nbsp;&nbsp; Viral conjuctivitis

6.4&nbsp;&nbsp;&nbsp; Allergic conjuctivitis

6.4.1&nbsp;&nbsp;&nbsp; Seasonal allergic conjunctivitis

6.4.2&nbsp;&nbsp;&nbsp; Perennial allergic conjunctivitis

6.4.3&nbsp;&nbsp;&nbsp; Other allergic conjunctivitis

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Topical

7.3&nbsp;&nbsp;&nbsp; Oral

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Formulation Type, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Tablets and capsules

8.3&nbsp;&nbsp;&nbsp; Ointment

8.4&nbsp;&nbsp;&nbsp; Drops

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

9.3&nbsp;&nbsp;&nbsp; Online pharmacies

9.4&nbsp;&nbsp;&nbsp; Retail pharmacies &amp; drug stores

9.5&nbsp;&nbsp;&nbsp; Other distribution channels

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Germany

10.3.2&nbsp;&nbsp;&nbsp; UK

10.3.3&nbsp;&nbsp;&nbsp; France

10.3.4&nbsp;&nbsp;&nbsp; Italy

10.3.5&nbsp;&nbsp;&nbsp; Spain

10.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; China

10.4.2&nbsp;&nbsp;&nbsp; Japan

10.4.3&nbsp;&nbsp;&nbsp; India

10.4.4&nbsp;&nbsp;&nbsp; Australia

10.4.5&nbsp;&nbsp;&nbsp; South Korea

10.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Mexico

10.5.3&nbsp;&nbsp;&nbsp; Argentina

10.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.2&nbsp;&nbsp;&nbsp; South Africa

10.6.3&nbsp;&nbsp;&nbsp; UAE

10.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

11.2&nbsp;&nbsp;&nbsp; AFT Pharmaceuticals

11.3&nbsp;&nbsp;&nbsp; Ajanta Pharma Limited

11.4&nbsp;&nbsp;&nbsp; Alembic Pharmaceuticals

11.5&nbsp;&nbsp;&nbsp; Bausch &amp; Lomb Incorporated

11.6&nbsp;&nbsp;&nbsp; Cipla, Inc.

11.7&nbsp;&nbsp;&nbsp; JAWA Pharmaceuticals Pvt. Ltd.

11.8&nbsp;&nbsp;&nbsp; Novartis AG

11.9&nbsp;&nbsp;&nbsp; NicOx SA

11.10&nbsp;&nbsp;&nbsp; Ocular Therapeutics, Inc.

11.11&nbsp;&nbsp;&nbsp; Santen Pharmaceuticals Co. Ltd.

11.12&nbsp;&nbsp;&nbsp; Sun Pharmaceuticals Industries Ltd.

11.13&nbsp;&nbsp;&nbsp; Spectra Vision Care Pvt. Ltd.

11.14&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd. 
&nbsp;

Conjunctivitis Treatment Market

Get a free sample of this report